Splice-region antisense composition and method
Antisense compositions targeted against an mRNA sequence coding for a selected protein, at a region having its 5′ end from 1 to about 25 base pairs downstream of a normal splice acceptor junction in the preprocessed mRNA, are disclosed. The antisense compound is RNase-inactive, and is preferably a phosphorodiamidate-linked morpholino oligonucleotide. Such targeting is effective to inhibit natural mRNA splice processing, produce splice variant mRNAs, and inhibit normal expression of the protein.
1. An antisense compound composed of a 2′-O-methyl modified backbone and a base sequence of 12 to 25 nucleotide bases which is complementary to a target region within one exon of multiple exons of a preprocessed mRNA encoding a human protein, wherein the 5′-end of the target region is 12 bases downstream of a normal splice acceptor site in said preprocessed mRNA.
2. The compound of claim 1 , which is about 24 nucleotide bases.
3. A composition, comprising an antisense compound of claim 1 and a pharmaceutical carrier.
4. The composition of claim 3 , formulated for intramuscular delivery.
5. The composition of claim 3 , formulated for intravenous (IV) infusion.
6. The composition of claim 3 , formulated for subcutaneous delivery.
7. A method of producing a splice variant mRNA in a human subject, comprising administering to the subject an antisense compound of claim 1 , wherein the antisense compound alters splicing of a preprocessed mRNA encoding a human protein, to produce a variant mRNA, wherein the variant mRNA expresses a variant protein.
8. The method of claim 7 , wherein said administering is by intramuscular delivery.
9. The method of claim 7 , wherein said administering is by intravenous (IV) infusion.
10. The method of claim 7 , wherein said administering is by subcutaneous delivery.